1. Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition
- Author
-
Sodhi, Jasleen K, Liu, Shuaibing, and Benet, Leslie Z
- Subjects
Pharmacology and Pharmaceutical Sciences ,Biomedical and Clinical Sciences ,Clinical Research ,Digestive Diseases ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Cancer ,ATP Binding Cassette Transporter ,Subfamily B ,Member 1 ,ATP Binding Cassette Transporter ,Subfamily G ,Member 2 ,Biological Transport ,Cytochrome P-450 CYP3A ,Drug Interactions ,Humans ,Intestinal Absorption ,Neoplasm Proteins ,Pyrazoles ,Pyridones ,apixaban ,bioavailability ,clearance ,complex drug-drug interactions ,mean absorption time ,Pharmacology & Pharmacy ,Pharmacology and pharmaceutical sciences - Abstract
PurposeThe involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in apixaban disposition based on in vitro studies. Recommendations against co-administration of apixaban with inhibitors of these efflux transporters can be found throughout the literature as well as in the apixaban FDA label. However, the clinical relevance of such findings is questionable due to the high permeability and high solubility characteristics of apixaban.MethodsUsing recently published methodologies to discern metabolic- from transporter- mediated drug-drug interactions, a critical evaluation of all published apixaban drug-drug interaction studies was conducted to investigate the purported clinical significance of efflux transporters in apixaban disposition.ResultsRational examination of these clinical studies using basic pharmacokinetic theory does not support the clinical significance of intestinal efflux transporters in apixaban disposition. Further, there is little evidence that efflux transporters are clinically significant determinants of systemic clearance.ConclusionsInhibition or induction of intestinal CYP3A4 can account for exposure changes of apixaban in all clinically significant drug-drug interactions, and lack of intestinal CYP3A4 inhibition can explain all studies with no exposure changes, regardless of the potential for these perpetrators to inhibit intestinal or systemic efflux transporters.
- Published
- 2020